Nestor Szerman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nestor Szerman has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Ignacio Basurte-Villamor
Department of Psychiatry, Fundacion Jimenez Diaz, Madrid, Spain
5 shared publications Pablo Vega
Institute for Addictions, Madrid Salud, Madrid City Council, Madrid, Spain
4 shared publications- Pablo Vega
Institute for Addictions, Madrid Salud, Madrid City Council, Madrid, Spain
4 shared publications Ignacio Basurte-Villamor
López Ibor Clinic, Madrid, Spain
3 shared publicationsCarlos Parro-Torres
Psychiatry Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
2 shared publications- Carlos Roncero
Department of Health Sciences, Miguel de Cervantes European University (UEMC), 47012 Valladolid, Spain
2 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
A comprehensive pilot care program for people suffering with chronic pain, opioid misuse risk and mental disorders
Objective: Opioid analgesics used to treat chronic pain may improve mood while reducing pain, which can contribute to persistent use and, in vulnerable patients, to problematic opioid use. The DOLMEN program was developed to address this problem from a multidimensional perspective.Methods: We implemented a multidisciplinary pilot program and conducted a prospective observational evaluation. Patients with chronic pain receiving opioid treatment were assessed for psychiatric symptoms, including depression, anxiety, ADHD, and substance use disorders. CYP2D6, CYP2C19, and OPRM1 genotypes were also determined. All patients received multidisciplinary treatment, including psychiatric, psychological, and psychoeducational interventions, as well as pharmacist-led interventions related to their opioid therapy.Results: The study included 81 patients, of whom 72 completed the group sessions. Most were women (67.9%), with a mean age of 52.7 years. At baseline, 26.0% showed low to severe problematic opioid use. Among the 68 patients who completed the program and had genetic information available, mean scores improved for CGI (3.7 to 3.0; p<0.0001), STAI-E (40.1 to 35.6; p=0.0004), STAI-R (41.0 to 37.9; p<0.0001), BDI-II (34.9 to 29.6; p<0.0001), and the EQ-5D-5L health score (33.2 to 40.3; p=0.0145). The OPRM1 rs1799971 polymorphism and the CYP2C19 phenotype were associated with STAI-R (p<0.05), but did not influence the improvement after intervention. The pharmacist made 78 recommendations to adjust therapy.Conclusions: The DOLMEN program was associated with improvements across several symptom domains in patients with chronic and emotional pain and problematic opioid use. Exploratory pharmacogenetic findings suggest that CYP2C19 phenotype and OPRM1 rs1799971 may identify patients with higher baseline trait anxiety. These findings support the feasibility of an integrated multidisciplinary approach and warrant confirmation in controlled studies.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA comprehensive pilot care program for people suffering with chronic pain, opioid misuse risk and mental disorders
Objective: Opioid analgesics used to treat chronic pain may improve mood while reducing pain, which can contribute to persistent use and, in vulnerable patients, to problematic opioid use. The DOLMEN program was developed to address this problem from a multidimensional perspective.Methods: We implemented a multidisciplinary pilot program and conducted a prospective observational evaluation. Patients with chronic pain receiving opioid treatment were assessed for psychiatric symptoms, including depression, anxiety, ADHD, and substance use disorders. CYP2D6, CYP2C19, and OPRM1 genotypes were also determined. All patients received multidisciplinary treatment, including psychiatric, psychological, and psychoeducational interventions, as well as pharmacist-led interventions related to their opioid therapy.Results: The study included 81 patients, of whom 72 completed the group sessions. Most were women (67.9%), with a mean age of 52.7 years. At baseline, 26.0% showed low to severe problematic opioid use. Among the 68 patients who completed the program and had genetic information available, mean scores improved for CGI (3.7 to 3.0; p<0.0001), STAI-E (40.1 to 35.6; p=0.0004), STAI-R (41.0 to 37.9; p<0.0001), BDI-II (34.9 to 29.6; p<0.0001), and the EQ-5D-5L health score (33.2 to 40.3; p=0.0145). The OPRM1 rs1799971 polymorphism and the CYP2C19 phenotype were associated with STAI-R (p<0.05), but did not influence the improvement after intervention. The pharmacist made 78 recommendations to adjust therapy.Conclusions: The DOLMEN program was associated with improvements across several symptom domains in patients with chronic and emotional pain and problematic opioid use. Exploratory pharmacogenetic findings suggest that CYP2C19 phenotype and OPRM1 rs1799971 may identify patients with higher baseline trait anxiety. These findings support the feasibility of an integrated multidisciplinary approach and warrant confirmation in controlled studies.
- 26 March 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Research Reviews
- Vol. 18
Treatment-refractory Addictions: Clinical Characterization and an Operational Model for Integrated Management
The current mental health system faces an important yet not well-understood problem, which involves addictions that do not respond to treatment. The cases present with ongoing substance abuse, multiple treatment failures, psychiatric conditions, social instability, and work-related problems. The absence of standardized operational criteria creates problems with immediate patient identification, comparing research study results, and healthcare providers' efforts to create structured treatment plans. The article combines existing data about treatment-resistant addiction to create an initial framework that explains its medical characteristics, brain functions, social aspects, and treatment approaches. The research uses depression and schizophrenia treatment-resistant frameworks to develop functional criteria, which include multiple treatment failures, ongoing disability, complex medical conditions, and inadequate response to optimal treatment protocols. Healthcare providers can identify actual refractoriness using established criteria that help distinguish it from pseudo-resistance, which occurs due to incorrect medical diagnoses, insufficient medication exposure, or non-compliance with treatment instructions. The research presents typical medical signs that appear in people who do not respond to substance use treatment through their impulsive behavior, their inability to identify emotions, their background of trauma, their presence of multiple psychiatric conditions, and their exposure to poverty and prison life. The review evaluates present-day pharmacological treatments that combine GLP-1 receptor agonists with ketamine and cannabidiol, partial agonists, and neuromodulation methods (rTMS and tDCS), as well as psychotherapeutic approaches (ACT, DBT, MBRP, and CRA) to improve treatment outcomes. We propose an operational system that integrates diagnostic evaluation with medication treatment and psychotherapy services, brain function assessments, and social assistance programs. This model is focused on a team-based approach aimed at delivering personalized medical care. Patients’ non-adherence is considered as a clinical issue rather than a factor of social labeling or exclusion. Empirical testing is needed to validate the proposed evaluation criteria, as well as treatment effectiveness in real-world settings should be confirmed to approve accessible and advanced care for all patients.
- 26 March 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Research Reviews
- Vol. 18
Treatment-refractory Addictions: Clinical Characterization and an Operational Model for Integrated Management
The current mental health system faces an important yet not well-understood problem, which involves addictions that do not respond to treatment. The cases present with ongoing substance abuse, multiple treatment failures, psychiatric conditions, social instability, and work-related problems. The absence of standardized operational criteria creates problems with immediate patient identification, comparing research study results, and healthcare providers' efforts to create structured treatment plans. The article combines existing data about treatment-resistant addiction to create an initial framework that explains its medical characteristics, brain functions, social aspects, and treatment approaches. The research uses depression and schizophrenia treatment-resistant frameworks to develop functional criteria, which include multiple treatment failures, ongoing disability, complex medical conditions, and inadequate response to optimal treatment protocols. Healthcare providers can identify actual refractoriness using established criteria that help distinguish it from pseudo-resistance, which occurs due to incorrect medical diagnoses, insufficient medication exposure, or non-compliance with treatment instructions. The research presents typical medical signs that appear in people who do not respond to substance use treatment through their impulsive behavior, their inability to identify emotions, their background of trauma, their presence of multiple psychiatric conditions, and their exposure to poverty and prison life. The review evaluates present-day pharmacological treatments that combine GLP-1 receptor agonists with ketamine and cannabidiol, partial agonists, and neuromodulation methods (rTMS and tDCS), as well as psychotherapeutic approaches (ACT, DBT, MBRP, and CRA) to improve treatment outcomes. We propose an operational system that integrates diagnostic evaluation with medication treatment and psychotherapy services, brain function assessments, and social assistance programs. This model is focused on a team-based approach aimed at delivering personalized medical care. Patients’ non-adherence is considered as a clinical issue rather than a factor of social labeling or exclusion. Empirical testing is needed to validate the proposed evaluation criteria, as well as treatment effectiveness in real-world settings should be confirmed to approve accessible and advanced care for all patients.
- Open Access
- 12 December 2025
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- p. 1-3
Dual disorders or dual diagnosis?
“Dual disorders” (DD) refers to the co-occurrence of addiction and other mental health conditions, which often interact and complicate care. Despite scientific evidence showing shared brain mechanisms, current diagnostic systems treat them separately, leading to fragmented treatment and stigma. The World Association on Dual Disorders urges adopting “dual disorders” as a unified term to improve clarity, care integration, and outcomes.
- 12 December 2025
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- p. 1-3
Open AccessDual disorders or dual diagnosis?
“Dual disorders” (DD) refers to the co-occurrence of addiction and other mental health conditions, which often interact and complicate care. Despite scientific evidence showing shared brain mechanisms, current diagnostic systems treat them separately, leading to fragmented treatment and stigma. The World Association on Dual Disorders urges adopting “dual disorders” as a unified term to improve clarity, care integration, and outcomes.
- Open Access
- 29 January 2025
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 16
Is there a risk of esketamine misuse in clinical practice?
In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating and remitting depressive symptoms, with sustained benefits observed for nearly 4.5 years. As the S-enantiomer of ketamine, esketamine’s dosing guidelines and strict medical supervision stem from prior research on ketamine’s use in depression and history as a recreational drug. Despite initial concerns, long-term clinical studies have not documented instances of abuse, misuse, addiction or withdrawal, and the same was found in case reports or subsamples of high-risk populations with comorbidities such as substance use disorder or alcohol use disorder. Esketamine has proven to be safe and well tolerated without fostering new-onset substance use in vulnerable groups. Real-world studies reinforced these observations, reporting no adverse events (AEs) related to pharmacological interactions of esketamine with any other substance, and no new-onset drug or alcohol misuse, craving, misuse or diversion of use. Reports of esketamine craving remain rare, with only one case report documented in 2022. Most drug-related AEs reported in pharmacovigilance databases are those identified in the product’s technical data sheet and with known reported frequency. More importantly, no register of illicit acquisition of esketamine or its tampering for obtaining ketamine or other altered products was found in our search. Overall, our review confirms esketamine’s safety across diverse patient populations, reassuring its responsible use and the scarcity of reports of abuse or misuse since its introduction to the market.
- 29 January 2025
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 16
Open AccessIs there a risk of esketamine misuse in clinical practice?
In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating and remitting depressive symptoms, with sustained benefits observed for nearly 4.5 years. As the S-enantiomer of ketamine, esketamine’s dosing guidelines and strict medical supervision stem from prior research on ketamine’s use in depression and history as a recreational drug. Despite initial concerns, long-term clinical studies have not documented instances of abuse, misuse, addiction or withdrawal, and the same was found in case reports or subsamples of high-risk populations with comorbidities such as substance use disorder or alcohol use disorder. Esketamine has proven to be safe and well tolerated without fostering new-onset substance use in vulnerable groups. Real-world studies reinforced these observations, reporting no adverse events (AEs) related to pharmacological interactions of esketamine with any other substance, and no new-onset drug or alcohol misuse, craving, misuse or diversion of use. Reports of esketamine craving remain rare, with only one case report documented in 2022. Most drug-related AEs reported in pharmacovigilance databases are those identified in the product’s technical data sheet and with known reported frequency. More importantly, no register of illicit acquisition of esketamine or its tampering for obtaining ketamine or other altered products was found in our search. Overall, our review confirms esketamine’s safety across diverse patient populations, reassuring its responsible use and the scarcity of reports of abuse or misuse since its introduction to the market.
- Open Access
- 11 October 2024
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 15, 1427561
Tobacco use disorder in patients with other mental disorders: a dual disorder perspective from clinical neuroscience
Tobacco smoking is the leading cause of disability and preventable deaths worldwide, but it should be differentiated from tobacco use disorder, which is, according to the Diagnostic and Statistical Manual of Mental Disorders, a bona fide mental disorder. The rapid delivery of nicotine to the brain activates acetylcholine receptors and stimulates the release of dopamine, both systems implicated in other mental disorders. Rates of tobacco use disorder are much higher among people suffering from other mental disorders and these patients find it more difficult to quit. Dual disorders, from a transdiagnostic perspective, identify patients with substance use disorder, in this case tobacco use disorder, and other mental disorders. A dual disorder is a complex clinical condition that is often underdiagnosed, undertreated, and difficult to manage. Appropriate and integrated tobacco use disorder treatment programs for people also suffering from other mental disorders could improve outcomes. Bio-psycho-social approaches to tobacco use disorder include specific biological treatments (e.g., bupropion, varenicline, cytisine, nicotine replacement therapy or deep trans-magnetic stimulation). However, these treatments don’t have the same outcomes in patients with dual disorders. Therefore, as in other dual disorders, harm reduction measures, such as vaping nicotine through electronic cigarettes or tobacco replacement therapies should be considered as alternative tools for dual tobacco use disorder management. These clinical considerations emerge from a narrative literature review and expert consensus and will specifically address considerations for changes in clinical practice to improve the treatment of tobacco use disorder and other mental disorders.
- 11 October 2024
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 15, 1427561
Open AccessTobacco use disorder in patients with other mental disorders: a dual disorder perspective from clinical neuroscience
Tobacco smoking is the leading cause of disability and preventable deaths worldwide, but it should be differentiated from tobacco use disorder, which is, according to the Diagnostic and Statistical Manual of Mental Disorders, a bona fide mental disorder. The rapid delivery of nicotine to the brain activates acetylcholine receptors and stimulates the release of dopamine, both systems implicated in other mental disorders. Rates of tobacco use disorder are much higher among people suffering from other mental disorders and these patients find it more difficult to quit. Dual disorders, from a transdiagnostic perspective, identify patients with substance use disorder, in this case tobacco use disorder, and other mental disorders. A dual disorder is a complex clinical condition that is often underdiagnosed, undertreated, and difficult to manage. Appropriate and integrated tobacco use disorder treatment programs for people also suffering from other mental disorders could improve outcomes. Bio-psycho-social approaches to tobacco use disorder include specific biological treatments (e.g., bupropion, varenicline, cytisine, nicotine replacement therapy or deep trans-magnetic stimulation). However, these treatments don’t have the same outcomes in patients with dual disorders. Therefore, as in other dual disorders, harm reduction measures, such as vaping nicotine through electronic cigarettes or tobacco replacement therapies should be considered as alternative tools for dual tobacco use disorder management. These clinical considerations emerge from a narrative literature review and expert consensus and will specifically address considerations for changes in clinical practice to improve the treatment of tobacco use disorder and other mental disorders.
- Open Access
- 25 September 2024
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 40 (3) , 167-175
Cariprazine as a maintenance treatment in dual schizophrenia: a 6-month observational study in patients with schizophrenia and cannabis use disorder
Schizophrenia is often associated with substance use disorders, particularly cannabis use disorder (CUD). However, treatments frequently fail to address both conditions simultaneously. This study aimed to evaluate the antipsychotic effectiveness of cariprazine in patients with both schizophrenia and CUD in a real-world setting. A 6-month observational study was conducted on 58 patients diagnosed with schizophrenia and CUD, treated with cariprazine. Antipsychotic effectiveness was measured using the Positive and Negative Syndrome Scale and the Clinical Global Impression-Schizophrenia Scale, along with the Improvement and Severity scales. Cannabis consumption and addiction severity were assessed using the Cannabis Abuse Screening Test and the Severity of Dependence Scale, while functioning was evaluated with the Sheehan Disability Inventory. Cariprazine treatment resulted in significant improvements in schizophrenia symptoms (Positive and Negative Syndrome Scale change: −47.88 points, P < 0.0001; Clinical Global Impression-Schizophrenia Scale change: −8.26 points, P < 0.0001). Cannabis use and dependence also decreased (Cannabis Abuse Screening Test change: −7.0 points, P < 0.0001; Severity of Dependence Scale change: −7.88 points, P < 0.0001), alongside improvements in functioning (Sheehan Disability Inventory change: −9.48 points, P < 0.0001). These results suggest that cariprazine is effective for both schizophrenia and CUD, though further research is needed to confirm these findings.
- 25 September 2024
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 40 (3) , 167-175
Open AccessCariprazine as a maintenance treatment in dual schizophrenia: a 6-month observational study in patients with schizophrenia and cannabis use disorder
Schizophrenia is often associated with substance use disorders, particularly cannabis use disorder (CUD). However, treatments frequently fail to address both conditions simultaneously. This study aimed to evaluate the antipsychotic effectiveness of cariprazine in patients with both schizophrenia and CUD in a real-world setting. A 6-month observational study was conducted on 58 patients diagnosed with schizophrenia and CUD, treated with cariprazine. Antipsychotic effectiveness was measured using the Positive and Negative Syndrome Scale and the Clinical Global Impression-Schizophrenia Scale, along with the Improvement and Severity scales. Cannabis consumption and addiction severity were assessed using the Cannabis Abuse Screening Test and the Severity of Dependence Scale, while functioning was evaluated with the Sheehan Disability Inventory. Cariprazine treatment resulted in significant improvements in schizophrenia symptoms (Positive and Negative Syndrome Scale change: −47.88 points, P < 0.0001; Clinical Global Impression-Schizophrenia Scale change: −8.26 points, P < 0.0001). Cannabis use and dependence also decreased (Cannabis Abuse Screening Test change: −7.0 points, P < 0.0001; Severity of Dependence Scale change: −7.88 points, P < 0.0001), alongside improvements in functioning (Sheehan Disability Inventory change: −9.48 points, P < 0.0001). These results suggest that cariprazine is effective for both schizophrenia and CUD, though further research is needed to confirm these findings.
- Open Access
- 11 December 2022
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 66, 78-91
Is there such a thing as gambling dual disorder? Preliminary evidence and clinical profiles
- 11 December 2022
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 66, 78-91
Open AccessIs there such a thing as gambling dual disorder? Preliminary evidence and clinical profiles
- Open Access
- 13 October 2022
- Published by Springer Nature in Translational Psychiatry
- Vol. 12 (1) , 1-6
Addictive and other mental disorders: a call for a standardized definition of dual disorders
The persistent difficulty in conceptualizing the relationship between addictive and other mental disorders stands out among the many challenges faced by the field of Psychiatry. The different philosophies and schools of thought about, and the sheer complexity of these highly prevalent clinical conditions make progress inherently difficult, not to mention the profusion of competing and sometimes contradictory terms that unnecessarily exacerbate the challenge. The lack of a standardized term adds confusion, fuels stigma, and contributes to a “wrong door syndrome” that captures the difficulty of not only diagnosing but also treating addictive and other mental disorders in an integrated manner. The World Association on Dual Disorders (WADD) proposes the adoption of the term “Dual Disorder” which, while still arbitrary, would help harmonize various clinical and research efforts by rallying around a single, more accurate, and less stigmatizing designation.
- 13 October 2022
- Published by Springer Nature in Translational Psychiatry
- Vol. 12 (1) , 1-6
Open AccessAddictive and other mental disorders: a call for a standardized definition of dual disorders
The persistent difficulty in conceptualizing the relationship between addictive and other mental disorders stands out among the many challenges faced by the field of Psychiatry. The different philosophies and schools of thought about, and the sheer complexity of these highly prevalent clinical conditions make progress inherently difficult, not to mention the profusion of competing and sometimes contradictory terms that unnecessarily exacerbate the challenge. The lack of a standardized term adds confusion, fuels stigma, and contributes to a “wrong door syndrome” that captures the difficulty of not only diagnosing but also treating addictive and other mental disorders in an integrated manner. The World Association on Dual Disorders (WADD) proposes the adoption of the term “Dual Disorder” which, while still arbitrary, would help harmonize various clinical and research efforts by rallying around a single, more accurate, and less stigmatizing designation.
- Open Access
- 1 May 2022
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 18, 965-976
A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment
Background: Limited studies have evaluated the effectiveness of vortioxetine in real-world settings, and none of them has involved patients with dual depression (major depressive disorder [MDD] and substance use disorder [SUD]). The objective of the study was to describe the effectiveness of vortioxetine in clinical practice and determine its effect on affective symptoms, cognitive function, quality of life, and substance use in patients with MDD and SUD. Methods: Post-authorization, retrospective, multicenter, descriptive, and observational study in 80 patients with MDD and SUD receiving a maintenance treatment with vortioxetine for six months between January 2017 and April 2021. Results: Compared with baseline, scores significantly decreased after 3 and 6 months of treatment in the Montgomery-Åsberg Depression Rating Scale total (from 28.9 to 17.7 and 12.0), and global functional impairment of the Sheehan Disability Inventory (from 26.3 to 19.1 and 16.7). The number of correct answers in the symbol digit modalities test significantly improved during vortioxetine treatment (from 40.4 to 43.8 and 48.4). Regarding the clinical global impression scale, the score for disease severity significantly decreased from 3.8 to 3.0 and 2.4. Compared with baseline, there was a significant reduction in consumption of practically all substances, especially of alcohol, cannabis, and cocaine. Conclusion: Vortioxetine was effective in clinical practice for alleviating depressive symptoms and functional impairment, and in improving cognitive and executive functions and disease severity in patients with MDD and SUD. Moreover, the treatment with vortioxetine favored a reduction in substance use and the severity of the SUDs.
- 1 May 2022
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 18, 965-976
Open AccessA Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment
Background: Limited studies have evaluated the effectiveness of vortioxetine in real-world settings, and none of them has involved patients with dual depression (major depressive disorder [MDD] and substance use disorder [SUD]). The objective of the study was to describe the effectiveness of vortioxetine in clinical practice and determine its effect on affective symptoms, cognitive function, quality of life, and substance use in patients with MDD and SUD. Methods: Post-authorization, retrospective, multicenter, descriptive, and observational study in 80 patients with MDD and SUD receiving a maintenance treatment with vortioxetine for six months between January 2017 and April 2021. Results: Compared with baseline, scores significantly decreased after 3 and 6 months of treatment in the Montgomery-Åsberg Depression Rating Scale total (from 28.9 to 17.7 and 12.0), and global functional impairment of the Sheehan Disability Inventory (from 26.3 to 19.1 and 16.7). The number of correct answers in the symbol digit modalities test significantly improved during vortioxetine treatment (from 40.4 to 43.8 and 48.4). Regarding the clinical global impression scale, the score for disease severity significantly decreased from 3.8 to 3.0 and 2.4. Compared with baseline, there was a significant reduction in consumption of practically all substances, especially of alcohol, cannabis, and cocaine. Conclusion: Vortioxetine was effective in clinical practice for alleviating depressive symptoms and functional impairment, and in improving cognitive and executive functions and disease severity in patients with MDD and SUD. Moreover, the treatment with vortioxetine favored a reduction in substance use and the severity of the SUDs.